JNJ

234.6

+0.18%↑

UNH

275.89

-2.31%↓

TMO

570.38

-1.39%↓

ABT

108.46

+0.03%↑

ISRG

474.71

-2.33%↓

JNJ

234.6

+0.18%↑

UNH

275.89

-2.31%↓

TMO

570.38

-1.39%↓

ABT

108.46

+0.03%↑

ISRG

474.71

-2.33%↓

JNJ

234.6

+0.18%↑

UNH

275.89

-2.31%↓

TMO

570.38

-1.39%↓

ABT

108.46

+0.03%↑

ISRG

474.71

-2.33%↓

JNJ

234.6

+0.18%↑

UNH

275.89

-2.31%↓

TMO

570.38

-1.39%↓

ABT

108.46

+0.03%↑

ISRG

474.71

-2.33%↓

JNJ

234.6

+0.18%↑

UNH

275.89

-2.31%↓

TMO

570.38

-1.39%↓

ABT

108.46

+0.03%↑

ISRG

474.71

-2.33%↓

Home・Akcijų sąrašas・Cogent Biosciences Inc

Cogent Biosciences Inc

Atidarymo kaina

35.73 -5.75

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

35.63

Max

37.61

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-7.4M -81M
Pelnas, tenkantis vienai akcijai	-0.5
Darbuotojai	205
EBITDA	-6.8M -79M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+40.16% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	3.6B 5.8B
Ankstesnė atidarymo kaina	41.48
Ankstesnė uždarymo kaina	35.73

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

4.88 / 5.87 Palaikymas ir pasipriešinimas

Cogent Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-03 23:11; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

2026-02-03 23:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-03 23:50; UTC

Rinkos pokalbiai

Nikkei May Decline After Hitting All-Time High -- Market Talk

2026-02-03 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026-02-03 23:41; UTC

Įsigijimai, susijungimai, perėmimai

KKR Makes AI Play With $10.9B Asia Data-Center Deal

2026-02-03 23:38; UTC

Uždarbis

AMD Sales Climb on Help From Data-Center Business -- Update

2026-02-03 23:29; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

2026-02-03 23:27; UTC

Įsigijimai, susijungimai, perėmimai

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

2026-02-03 23:25; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Consortium Expects Deal to Close by Early 2H of 2026

2026-02-03 23:23; UTC

Įsigijimai, susijungimai, perėmimai

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

2026-02-03 23:22; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

2026-02-03 23:19; UTC

Rinkos pokalbiai

Australia Gold Miners Tipped to Rally Higher -- Market Talk

2026-02-03 23:19; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-03 22:56; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

2026-02-03 22:40; UTC

Uždarbis

Amdocs Extends Collaboration With T-Mobile

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q Adj EPS $1.81

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q Rev $1.16B

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q EPS $1.45 >

2026-02-03 22:38; UTC

Uždarbis

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

2026-02-03 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

2026-02-03 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

2026-02-03 22:14; UTC

Uždarbis

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

2026-02-03 22:13; UTC

Uždarbis

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

2026-02-03 22:12; UTC

Uždarbis

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

2026-02-03 22:10; UTC

Uždarbis

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

2026-02-03 22:10; UTC

Uždarbis

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

2026-02-03 22:10; UTC

Rinkos pokalbiai

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

2026-02-03 22:10; UTC

Uždarbis

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

2026-02-03 22:09; UTC

Uždarbis

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

2026-02-03 22:09; UTC

Uždarbis

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Akcijų palyginimas

Kainos pokytis

Cogent Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

40.16% į viršų

12 mėnesių prognozė

Vidutinis 50.33 USD 40.16%

Aukščiausias 67 USD

Žemiausias 34 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Cogent Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių Cogent Biosciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

4.88 / 5.87Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.